177Lu-PNT2002 (formerly 177Lu-PSMA-I&T is a peptide developed by the Technical University Munich and Scintomics. It was labeled also with 68Ga and 111In for respectively PET and SPECTimaging (but also radio-guided surgery), hence creating a PSMA-probes platform. This drug is an alternative to 177Lu-PSMA-617. The US company Point Biopharma acquired the rights for this molecule and initiated a Phase III trial in December 2020 with funding from Research Alliance Corp. The drug could reach the market by end of 2023 or 2024.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.